Maze Therapeutics (MAZE)
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic disea...
- Open
- 27.050
- High
- 27.790
- Low
- 26.500
- Prev. Close
- 27.180
- Volume
- 589.35K
- Turnover
- 15.83M
- Avg Price
- 26.862
- Bid/Ask Ratio
- --
- Amplitude
- 4.75%
- 52wk High
- 53.650
- Volume Ratio
- 1.92
- Turnover Ratio
- 1.58%
- 52wk Low
- 21.950
- Float Mkt Cap
- 992.72M
- Market CapUSD
- 1.48B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -2.40
- EPSDynamic
- -2.48
- EPSStatic
- --
- BVPS
- 8.16
- P/B
- 3.27
- Circulating Supply
- 37.25M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 55.55M
- Min lot size
- 1
- Currency
- USD
Maze Therapeutics Analyst Rating
View moreForecast & Rating
Sep 25, 2026Price forecast
$61.50130.77%
Forecast & RatingStrong buy
13analysts
- Strong buy92.31%
- Buy7.69%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 3 hours ago
Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $202,920.75
- benzinga_article · Sep 23 at 02:02 PM
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
- Market Beat · Sep 23 at 12:24 PM
Maze Therapeutics (NASDAQ:MAZE) Receives Outperform Rating from Wedbush
- Unusual Whales · Sep 22 at 06:10 PM
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
- TradingView · Sep 22 at 04:07 PM
BTIG reiterates Buy rating on Maze Therapeutics, $46 price target
- Tip Ranks · Sep 22 at 02:35 PM
Maze Therapeutics Reiterated Buy as APOL1 Opportunity Expands; $64 Price Target Maintained
